About Anteris Technologies Global Cor (AVR)

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.

AVR Key Statistics

AVR Price Performance

Anteris Technologies Global Cor stock has returned -0.31% over the past day, -0.16% over the past week, +11.44% over the past month, and +40.98% over the past three months. The stock trades between a 52-week low of $2.34 and a high of $8.08.